Analysts Anticipate Eli Lilly and Co (LLY) Will Announce Quarterly Sales of $5.47 Billion

Wall Street brokerages expect Eli Lilly and Co (NYSE:LLY) to report sales of $5.47 billion for the current quarter, according to Zacks. Three analysts have issued estimates for Eli Lilly and’s earnings, with the highest sales estimate coming in at $5.53 billion and the lowest estimate coming in at $5.42 billion. Eli Lilly and reported sales of $5.23 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.6%. The business is scheduled to report its next quarterly earnings results on Tuesday, April 24th.

On average, analysts expect that Eli Lilly and will report full year sales of $5.47 billion for the current financial year, with estimates ranging from $23.05 billion to $23.67 billion. For the next fiscal year, analysts forecast that the company will post sales of $23.89 billion per share, with estimates ranging from $23.30 billion to $24.36 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Eli Lilly and.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 EPS.

A number of equities research analysts have weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, October 24th. Barclays boosted their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, October 13th. Berenberg Bank reiterated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $92.02.

Shares of Eli Lilly and (LLY) opened at $77.99 on Wednesday. The firm has a market cap of $85,870.00, a price-to-earnings ratio of -389.95, a price-to-earnings-growth ratio of 1.49 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and has a 12 month low of $75.71 and a 12 month high of $89.09.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.88%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is -1,040.00%.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold a total of 261,613 shares of company stock valued at $22,894,997 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of the stock. Sfmg LLC boosted its holdings in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after buying an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. boosted its holdings in Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after buying an additional 24 shares during the period. YorkBridge Wealth Partners LLC boosted its holdings in Eli Lilly and by 0.8% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after buying an additional 24 shares during the period. BSW Wealth Partners boosted its holdings in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after buying an additional 27 shares during the period. Finally, Pathstone Family Office LLC boosted its holdings in Eli Lilly and by 100.0% in the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after buying an additional 29 shares during the period. 76.45% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/07/analysts-anticipate-eli-lilly-and-co-lly-will-announce-quarterly-sales-of-5-47-billion.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply